Skip to main content
Top
Published in: Internal and Emergency Medicine 1/2013

01-04-2013 | Review

Gut microbiota and metabolic syndrome

Authors: Francesca D’Aversa, Annalisa Tortora, Gianluca Ianiro, Francesca Romana Ponziani, Brigida Eleonora Annicchiarico, Antonio Gasbarrini

Published in: Internal and Emergency Medicine | Special Issue 1/2013

Login to get access

Abstract

Symbiosis is the result of the relationship between gut microbiota and human surfaces; in fact, it regulates many functions such as metabolic and protective ones. It is widely known that any changes in the microbes in gut microbiota (dysbiosis) and the regulation of mucosal and systemic host’s immunity have been linked to different diseases such as metabolic syndromes and associated disorders. Recent studies report an aberrant gut microbiota and an alteration of gut microbial metabolic activities in obese subjects, with an important influence of a number of human physiological functions. Most studies suggest that diet, especially the high-fat low-fiber western-style diet, dramatically impacts on gut microbiota composition and functions in those patients with metabolic syndrome. A deeper knowledge of a specific microbiota profile associated with increased risk of metabolic disease and its subsequent modification induced by prebiotics, probiotics or targeted antibiotics will be necessary for the development of new therapeutic approaches in the treatment of metabolic disease.
Literature
1.
go back to reference Kau AL et al (2011) Human nutrition, the gut microbiome and the immune system. Nature 474:327–336PubMedCrossRef Kau AL et al (2011) Human nutrition, the gut microbiome and the immune system. Nature 474:327–336PubMedCrossRef
2.
go back to reference Tremaroli V, Backhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature 489:242–249PubMedCrossRef Tremaroli V, Backhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature 489:242–249PubMedCrossRef
3.
go back to reference Scarpellini E et al (2010) Gut microbiota and obesity. Intern Emerg Med Suppl 1:S53–S56CrossRef Scarpellini E et al (2010) Gut microbiota and obesity. Intern Emerg Med Suppl 1:S53–S56CrossRef
4.
go back to reference Manco M, Putignani L, Bottazzo GF (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31:817–844PubMedCrossRef Manco M, Putignani L, Bottazzo GF (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31:817–844PubMedCrossRef
5.
go back to reference Backhed F et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101:15718–15723PubMedCrossRef Backhed F et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101:15718–15723PubMedCrossRef
6.
go back to reference Ley RE et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023PubMedCrossRef Ley RE et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023PubMedCrossRef
7.
go back to reference Murphy EF et al (2010) Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59:1635–1642PubMedCrossRef Murphy EF et al (2010) Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59:1635–1642PubMedCrossRef
8.
go back to reference Wu GD et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108PubMedCrossRef Wu GD et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108PubMedCrossRef
9.
go back to reference Cani PD et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103PubMedCrossRef Cani PD et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103PubMedCrossRef
10.
go back to reference Ojetti V et al (2009) Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 5:675–682PubMedCrossRef Ojetti V et al (2009) Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 5:675–682PubMedCrossRef
11.
go back to reference Delzenne NM et al (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7:639–646PubMedCrossRef Delzenne NM et al (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7:639–646PubMedCrossRef
12.
go back to reference Cani PD et al (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutri 90:1236–1243CrossRef Cani PD et al (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutri 90:1236–1243CrossRef
Metadata
Title
Gut microbiota and metabolic syndrome
Authors
Francesca D’Aversa
Annalisa Tortora
Gianluca Ianiro
Francesca Romana Ponziani
Brigida Eleonora Annicchiarico
Antonio Gasbarrini
Publication date
01-04-2013
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue Special Issue 1/2013
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-013-0916-z

Other articles of this Special Issue 1/2013

Internal and Emergency Medicine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine